Almela Maria Jesus, Lozano Sonia, Lelièvre Joël, Colmenarejo Gonzalo, Coterón José Miguel, Rodrigues Janneth, Gonzalez Carolina, Herreros Esperanza
GlaxoSmithKline, Tres Cantos Medicines Development Campus-Diseases of the Developing World, Severo Ochoa 2, Tres Cantos, 28760, Madrid, Spain; Universidad Nacional de Educación a Distancia (UNED), C/ Senda del Rey 11, 28040, Madrid, Spain.
GlaxoSmithKline, Tres Cantos Medicines Development Campus-Diseases of the Developing World, Severo Ochoa 2, Tres Cantos, 28760, Madrid, Spain.
PLoS One. 2015 Aug 28;10(8):e0135139. doi: 10.1371/journal.pone.0135139. eCollection 2015.
The discovery of new antimalarials with transmission blocking activity remains a key issue in efforts to control malaria and eventually eradicate the disease. Recently, high-throughput screening (HTS) assays have been successfully applied to Plasmodium falciparum asexual stages to screen millions of compounds, with the identification of thousands of new active molecules, some of which are already in clinical phases. The same approach has now been applied to identify compounds that are active against P. falciparum gametocytes, the parasite stage responsible for transmission. This study reports screening results for the Tres Cantos Antimalarial Set (TCAMS), of approximately 13,533 molecules, against P. falciparum stage V gametocytes. Secondary confirmation and cytotoxicity assays led to the identification of 98 selective molecules with dual activity against gametocytes and asexual stages. Hit compounds were chemically clustered and analyzed for appropriate physicochemical properties. The TCAMS chemical space around the prioritized hits was also studied. A selection of hit compounds was assessed ex vivo in the standard membrane feeding assay and demonstrated complete block in transmission. As a result of this effort, new chemical structures not connected to previously described antimalarials have been identified. This new set of compounds may serve as starting points for future drug discovery programs as well as tool compounds for identifying new modes of action involved in malaria transmission.
发现具有传播阻断活性的新型抗疟药仍然是控制疟疾并最终根除该疾病的关键问题。最近,高通量筛选(HTS)检测已成功应用于恶性疟原虫的无性阶段,以筛选数百万种化合物,鉴定出数千种新的活性分子,其中一些已进入临床阶段。现在,同样的方法已被用于鉴定对恶性疟原虫配子体(负责传播的寄生虫阶段)有活性的化合物。本研究报告了针对约13533种分子的特雷斯坎托斯抗疟药组合(TCAMS)对恶性疟原虫V期配子体的筛选结果。二次确认和细胞毒性检测导致鉴定出98种对配子体和无性阶段具有双重活性的选择性分子。对命中化合物进行化学聚类并分析其适当的物理化学性质。还研究了优先命中化合物周围的TCAMS化学空间。在标准膜饲法中对一系列命中化合物进行了体外评估,结果表明其完全阻断了传播。通过这项工作,已鉴定出与先前描述的抗疟药无关的新化学结构。这组新化合物可作为未来药物发现计划的起点,以及用于识别疟疾传播中涉及的新作用模式的工具化合物。